Hutchison China MediTech
Hong Kong, China

Hutchison China MediTech (Chi-Med), a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

Hutchison China MediTech (Chi-Med) continues to gather momentum as its pipeline gets closer to unlocking its potential. Increased visibility for the three lead assets with multiple catalysts in the next 6 to 18 months suggest significant upside potential. In China, Chi-Med is leveraging its established base to build a fully integrated oncology business, with its c 320-strong China Oncology commercial team set to take over Elunate marketing from October and execute its first unpartnered China launch in Q420 assuming surufatinib approval. A ninth drug candidate discovered in-house (HMPL-306) has entered the clinic in China, while five assets are in development for global markets. The first FDA submission (surufatinib) should start before year-end, with fruquintinib and savolitinib in or approaching global registration trials. Our updated valuation is £5.87/share or $38.17/ADS.

Market information



Innovative pipeline closer to realising its potential
Update | 10 Aug 2020
General Atlantic invests $100m at 10% premium
Lighthouse | 25 Jun 2020
ASCO 2020: savo and suru data drives regulatory progress
Update | 04 Jun 2020

Recent News

Plans to submit surufatinib MAA following EMA CHMP scientific advice
10 Aug 2020
H120 interims and clinical update
30 Jul 2020
Chi-Med and Eli Lilly to collaborate in commercializing Elunate in China
28 Jul 2020
China NDA for savolitinib in NSCLC granted Priority Review
28 Jul 2020